Former Chief Commercial Officer · MAXCYTE, INC. (MXCT)

Brad Calvin

FY2020 is the first fiscal year CompBrief holds for Brad Calvin as a named executive officer of MAXCYTE; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,092,089

Salary $371,667

3rd of 3 named executive officers at Maxcyte by FY2020 total.

3 named officers on file for MAXCYTE, FY2020

Brad Calvin’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how MAXCYTE’s whole pay program stands against its peers

  • MAXCYTE’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MXCT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed October 1, 2021 (DEF 14A).

Free

Get Brad Calvin’s full pay file as a PDF — free

More than this page: up to 10 years of Brad’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Brad Calvin compensation by year

MAXCYTE Summary Compensation Table · the one fiscal year held
In US dollars, as MAXCYTE reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$371,667
Option awards$368,106
Non-equity incentive$334,800
All other$17,516
Total$1,092,089

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MAXCYTE, INC. DEF 14A filed October 1, 2021, accession 0001104659-21-121580, and prior-year filings. Open the filing on EDGAR.

How this page was built: the MAXCYTE, INC. filed document, accession 0001104659-21-121580. Every figure is read from that document and cited to the page and table it appears in. Filed October 1, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option33,333—$3.42
Option49,479—$3.32
Option70,313—$2.43
Option96,354—$1.86
Option117,187—$4.51

Per the Outstanding Equity Awards at Fiscal Year-End table in MAXCYTE, INC.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

MAXCYTE’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Amanda MurphyFormer Chief Financial Officer$2,778,295
Doug DoerflerPresident, Chief Executive Officer and Director$1,223,727
Brad Calvin · this pageFormer Chief Commercial Officer$1,092,089

The full MAXCYTE compensation record

free company brief

This page is one person within MAXCYTE's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MAXCYTE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Brad Calvin's compensation dossier · One-time report. No refunds.